Use of gonadotrophin-releasing hormone agonists to trigger ovulation

Human Fertility

Volumn 5, Issue 1, 2002, Pages

  Tay, Clement C K ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROGEN; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; STEROID; TRIPTORELIN;

ANOVULATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS LUTEUM FUNCTION; DOWN REGULATION; DRUG COMPETITION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FERTILIZATION; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HIGH RISK PATIENT; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS FUNCTION; INCIDENCE; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; INTRAUTERINE INSEMINATION; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MULTICENTER STUDY; OOCYTE MATURATION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; TREATMENT PLANNING;

EID: 0036130048     PISSN: 14647273     EISSN: None     Source Type: Journal    
DOI: 10.1080/1464727992000199811     Document Type: Conference Paper

References (34)

1. Disappearance of exogenously administered human chorionic gonadotropin
2. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome
3. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation
4. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomised, multicentre trial
5. Minimal ovarian stimulation for IVF: Appraisal of potential benefits and drawbacks
6. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility
7. Evidence of an adverse effect of elevated serum estradiol concentrations on embryo implantation
8. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization
9. Hormonal dynamics at midcycle: A re-evaluation
10. A new approach to the management of patients at risk of ovarian hyperstimulation in an in vitro fertilization program
11. Recombinant human luteinizing hormone to mimic mid-cycle LH surge
12. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist
13. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: Preliminary report
14. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: Causes and implications
15. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovary disease gonadotropin hyperstimulated cycles
16. A randomised three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration
17. 'Triggering' of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF)
18. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
19. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
20. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
21. Induction of final oocyte maturation by a single dose of GnRH agonist after ganirelix treatment
22. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist
23. Pharmacokinetics of recombinant human luteinizing hormone, intramuscular and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone
24. The use of LHRH agonists to induce ovulation
25. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: A comparison of 761 cycles
26. Gonadotropin-releasing hormone agonist versus chorionic gonadotropin for triggering follicular maturation in in vitro fertilization
27. The luteinizing hormone surge - The final stage in ovulation induction: Modern aspects of ovulation triggering
28. Ovarian response in women to recombinant follicle-stimulating hormone and luteinizing hormone: A role for LH in the final stages of follicle maturation
29. Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome
30. The ovarian hyperstimulation syndrome
31. Recombinant follicle-stimulating hormone induces ovulation and tissue plasminogen activator expression in hypophysectomised rats
32. A novel regimen of gonadotrophin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: Controlled restoration of gonadotrophin secretion and ovulation induction
33. FSH-induced resumption of meiosis in mouse oocytes: Effects of different isoforms
34. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkey